Aardvark Therapeutics (AARD) Return on Capital Employed (2025 - 2026)
Aardvark Therapeutics (AARD) posted Return on Capital Employed of 77.6% for Q1 2026, down 41.86% sequentially from 54.71% in Q4 2025, and down 4967.0% YoY from 1.59% in Q1 2025.
Aardvark Therapeutics (AARD) Return on Capital Employed (2025 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Return on Capital Employed for 2 years, with the latest figure at 77.6% in Q1 2026.
- Quarterly Return on Capital Employed fell 4967.0% year-over-year to 77.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77.6% (down 4967.0% YoY) and the FY2025 annual result came in at 72.27%, changed N/A from the prior year.
- Return on Capital Employed retreated to 77.6% in Q1 2026 per AARD's latest filing, from 54.71% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 27.93% in Q1 2025 and troughed at 77.6% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | -88.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -88.42% |
| Mar 31, 2026 | -77.60% |
| Dec 31, 2025 | -54.71% |
| Sep 30, 2025 | -41.25% |
| Jun 30, 2025 | -28.79% |
| Mar 31, 2025 | -27.93% |